Medical experts compare the toxicity profiles of FTD/TPI plus bevacizumab, regorafenib, and fruquintinib, and discuss practical strategies for managing treatment-related toxicities with these ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback